Scholarlink

<p>Iron deficiency anaemia is a global health issue affecting millions of people. Though effective, conventional iron sources used for supplementation often cause gastrointestinal side effects. This preclinical study evaluated the efficacy and tolerability of three iron supplements—ferrous bisglycinate, LIPOFER™ microcapsules (Def-LFe1), and a commercially available microencapsulated iron pyrophosphate (Def-Fe2)—in reversing diet-induced iron deficiency in rats compared to FeSO<sub>4</sub>. The study included three phases: (a) First, animals underwent a 24-day iron depletion period; (b) then, animals were exposed to a 21-day repletion period, receiving treatments at a human-equivalent dose of 80&#xa0;mg of elemental iron; and (c) finally, to evaluate gastrointestinal tolerability, animals were supplemented with each treatment for 9 weeks. All supplements reversed iron deficiency within 14 days without adverse gastrointestinal effects. However, based on the decrease in TIBC and transferrin levels, coupled with the higher haemoglobin levels, Def-LFe1 demonstrated a higher absorption rate than Def-Fe2. In addition, the group supplemented with LIPOFER™ showed higher feed efficiency, especially compared to the control and FeSO<sub>4</sub> groups. FeSO<sub>4</sub> increased IL-6 gene expression in the colon, while Def-LFe1 did not. These findings highlight LIPOFER™ as a promising alternative to conventional iron supplementation. Further studies should be conducted to clarify these issues.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative study of the effects of different iron sources on bioavailability and gastrointestinal tolerability in iron-deficient rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Roger Mariné-Casadó,
  • Yaiza Tobajas,
  • Anna Antolín,
  • Teresa Negra,
  • Alan Connolly,
  • Juan María Alcaide-Hidalgo,
  • Antoni Caimari

摘要

Iron deficiency anaemia is a global health issue affecting millions of people. Though effective, conventional iron sources used for supplementation often cause gastrointestinal side effects. This preclinical study evaluated the efficacy and tolerability of three iron supplements—ferrous bisglycinate, LIPOFER™ microcapsules (Def-LFe1), and a commercially available microencapsulated iron pyrophosphate (Def-Fe2)—in reversing diet-induced iron deficiency in rats compared to FeSO4. The study included three phases: (a) First, animals underwent a 24-day iron depletion period; (b) then, animals were exposed to a 21-day repletion period, receiving treatments at a human-equivalent dose of 80 mg of elemental iron; and (c) finally, to evaluate gastrointestinal tolerability, animals were supplemented with each treatment for 9 weeks. All supplements reversed iron deficiency within 14 days without adverse gastrointestinal effects. However, based on the decrease in TIBC and transferrin levels, coupled with the higher haemoglobin levels, Def-LFe1 demonstrated a higher absorption rate than Def-Fe2. In addition, the group supplemented with LIPOFER™ showed higher feed efficiency, especially compared to the control and FeSO4 groups. FeSO4 increased IL-6 gene expression in the colon, while Def-LFe1 did not. These findings highlight LIPOFER™ as a promising alternative to conventional iron supplementation. Further studies should be conducted to clarify these issues.